Abstract
At the center of robust global animal health product growth, the U.S. market
for pet medications is going gangbusters, with continued double-digit sales
gains predicted for the foreseeable future as all of the world' s largest
pharmaceutical companies move full-force into the segment, adapting human
technologies and developing pet-specific ones. Also driving market growth are
the aging pet population and rising rates of pet overweight/obesity, spurring
the need for new product types. Although antiparasitics (flea/tick products
and heartworm remedies) remain at the core of the market- Merial' s Frontline
(fipronil) achieved “blockbuster” billion-dollar status in 2007,
and Bayer' s Advantage is also going strong- companies are now branching out
with new consumer-targeted pet medications, such as Pfizer' s Slentrol for
weight-loss and Eli Lilly' s Reconcile for separation anxiety.
Bringing in broad pet market perspective based on more than a dozen other pet
market reports, along with a unique “cross-market” focus examining
trends in both the veterinary (pharmaceutical) and retail (OTC) sectors, this
all-new report from Packaged Facts analyzes the market for medications for
dogs and cats, with a particular focus on products marketed directly to
consumers. Areas covered include parasite prevention and control (flea, tick,
heartworm, etc.), pain management (focusing on non-steroidal anti-inflammatory
drugs), mood disorders, overweight/obesity, cognitive dysfunction and oral
care. Top U.S. marketers profiled include all of the largest pharmaceutical
companies (Pfizer, Intervet-Schering, Bayer, Fort Dodge, Novartis, etc.) as
well as the top marketers of retail pet health lines (Central Garden & Pet,
Hartz, Sergeant' s).
Other high-interest areas examined in this report- all from the perspective of
their potential impact on future market performance- include product diversion
outside the veterinary channel, growth of online retailing via outfits
including PetMed Express, the effects of the 2008 economic crisis, and the
possibility of ethical brands' moving officially into retail channels. Retail
sales are quantified and projected forward through 2012, while the retail
performance of pet medication marketers and brands is evaluated using
Information Resources, Inc. InfoScan Review data. In addition, uniquely
cross-tabulated consumer survey data from Simmons Market Research Bureau
provides penetrating insight into pet medication consumer usage rates,
demographics and psychographics.
| 
View Cart
